NSE ScannerChemicals · Chemicals: Specialty · NSE: CAMLINFINE · data 2026-10-31
Camlin Fine Sciences Limited
In plain words
Price: 58.3% below its 52-week high of ₹201.79.
Delivery: 41.8% of traded shares were kept for delivery over the last 10 sessions, against 48.2% over the last 60.
Latest results: a net loss of ₹32 cr for the quarter ended Jun 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹1,862 cr |
| Net profit (last 12 months) | ₹6 cr |
| Sales growth, 3 years (yearly) | 0.8% |
| Profit growth, 3 years (yearly) | -19.1% |
At a glance
Promoters 48.0% (-1.0 pts in a year), pledged 16.2%, institutions 6.3%.
P/E 392.4, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE -2.8%, ROCE 2.3%, operating margin 0.9%: how much profit it earns on the money it uses.
Debt/equity 0.69, Profit growth -19.1% and sales growth 0.8% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (-2.8%).
- Thin operating margin (0.9%).
- Profit fell 19.1% a year over 3 years.
- Slow sales growth (0.8% a year over 3 years).
- Promoters have pledged 16.2% of their shares.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
CAMLINFINE Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹519.88 crore, up 22.7% YoY and up 22.4% QoQ.
Net loss was ₹31.71 crore, a bigger loss than a year ago and a turn to loss from a profit last quarter.
Operating margin was 1.8% (4.5% a year ago).
EPS was -₹1.65, more negative than a year ago and negative against a positive EPS last quarter.
CAMLINFINE के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹519.88 करोड़; पिछले साल की तुलना में 22.7% की बढ़त, पिछली तिमाही की तुलना में 22.4% की बढ़त।
शुद्ध घाटा: ₹31.71 करोड़; एक साल पहले से घाटा बढ़ा, पिछली तिमाही के मुनाफ़े से घाटे में आया।
ऑपरेटिंग मार्जिन: 1.8% (एक साल पहले 4.5%)।
EPS: -₹1.65; एक साल पहले से अधिक ऋणात्मक, पिछली तिमाही के धनात्मक EPS से ऋणात्मक हुआ।
CAMLINFINEના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹519.88 કરોડ; ગયા વર્ષની સરખામણીએ 22.7% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 22.4% વધારો.
ચોખ્ખી ખોટ: ₹31.71 કરોડ; એક વર્ષ પહેલાંની સરખામણીએ ખોટ વધી, ગયા ક્વાર્ટરની સરખામણીએ નફામાંથી ખોટમાં આવી.
ઓપરેટિંગ માર્જિન: 1.8% (એક વર્ષ પહેલાં 4.5%).
EPS: -₹1.65; એક વર્ષ પહેલાંના કરતાં વધુ નકારાત્મક, ગયા ક્વાર્ટરના હકારાત્મક EPSથી નકારાત્મક થઈ.
Written from the filed numbers. Not a recommendation.
Smart-money activity
9/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 4/30: Delivery 42.6% over the last 20 sessions vs 38.1% in the 40 before (1.12x); shares delivered per day 0.56x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Rights
- 11 Aug 26Results Q1 FY27 results: loss widened vs a year ago -13.2% next session
- 26 May 26Results Q4 FY26 results: turned to profit vs a year ago +6.1% next session
- 13 Feb 26Results Q3 FY26 results: loss widened vs a year ago -11.6% next session
- 10 Nov 25Results Q2 FY26 results: loss narrowed vs a year ago -13.5% next session
- 8 Aug 25Results Q1 FY26 results: loss narrowed vs a year ago -7.5% next session
- 23 May 25Results Q4 FY25 results: loss narrowed vs a year ago +12.1% next session
- 14 Feb 25Results Q3 FY25 results: loss narrowed vs a year ago +5.6% next session
- 8 Jan 25Rights Rights issue 5:41 · premium ₹109 (ex-date) -4.9% next session
- 11 Nov 24Results Q2 FY25 results: loss widened vs a year ago -0.3% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹520 cr | ₹-32 cr | — | 1.8% | -1.65 |
| Mar 2026 | ₹425 cr | ₹88 cr | — | 5.0% | 4.59 |
| Dec 2025 | ₹457 cr | ₹-36 cr | — | 4.8% | -1.91 |
| Sept 2025 | ₹460 cr | ₹-14 cr | — | 7.3% | -0.76 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 48.03% | 48.03% | 48.03% | 48.03% |
| Foreign institutions (FII) | 0.95% | 0.91% | 0.94% | 2.12% |
| Domestic institutions (DII) | 5.32% | 5.42% | 7.70% | 7.77% |
| Mutual funds | 4.97% | 5.12% | 6.80% | 7.00% |
| Retail investors | 23.19% | 21.34% | 19.51% | 18.95% |
| Number of shareholders | 56,981 | 55,178 | 52,232 | 52,357 |
Common questions
What was Camlin Fine Sciences Limited's latest quarterly profit?
Camlin Fine Sciences Limited reported a net loss of ₹32 cr for the quarter ended Jun 2026, on revenue of ₹520 cr.
How much do promoters hold in Camlin Fine Sciences Limited?
Promoters held 48.03% of Camlin Fine Sciences Limited at the end of Sept 2026, with 16.20% of promoter shares pledged.
Is Camlin Fine Sciences Limited debt-free?
Its latest reported debt-to-equity ratio is 0.69.
What is Camlin Fine Sciences Limited's P/E ratio?
About 392.4, based on the last 12 months' earnings and a price of ₹84.1 (data 2026-10-31).
What is the 52-week high and low of Camlin Fine Sciences Limited?
The 52-week high is ₹201.79 and the 52-week low is ₹78.8.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Camlin Fine Sciences Limited | ₹84.1 | ₹1,615 cr | 392.4 | — | -2.8% | 2.3% | 0.69 | -58.5% |
| S H Kelkar and Company Ltd | ₹125.34 | ₹1,740 cr | 19.5 | — | 5.3% | 8.5% | 0.76 | -44.9% |
| IG Petrochemicals Ltd. | ₹531.1 | ₹1,636 cr | 20 | — | 0.2% | 4.4% | 0.27 | +27.4% |
| Fischer Medical Ventures Ltd | ₹24.79 | ₹1,620 cr | 55.6 | — | 8.9% | 12.8% | 0.28 | -78.8% |
| Bhageria Industries Ltd. | ₹362.45 | ₹1,581 cr | 14 | 2.3 | 8% | 8% | 0.19 | +68.4% |
| Thirumalai Chemicals Limited | ₹114.33 | ₹1,374 cr | — | — | -12.3% | -3.5% | 1.39 | -59.4% |
Compare CAMLINFINE with SHK in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open CAMLINFINE in NSE Scanner →